Gsa Capital Partners LLP Immuno Gen, Inc. Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 16, 2024	SELL	$12.46 - $29.95 $1.2 Million - $2.88 Million	-96,299 Reduced 84.36%	17,856 $529,000
Q3 2023 Nov 15, 2023	BUY	$14.09 - $19.87 $1.11 Million - $1.57 Million	78,791 Added 222.8%	114,155 $1.81 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $20,865 - $111,558	5,564 Added 18.67%	35,364 $667,000
Q1 2023 May 12, 2023	BUY	$3.67 - $4.92 $109,366 - $146,616	29,800 New	29,800 $114,000
Q1 2022 May 11, 2022	SELL	$4.26 - $7.48 $160,525 - $281,861	-37,682 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $49,599 - $78,315	10,442 Added 38.33%	37,682 $280,000
Q3 2021 Nov 12, 2021	BUY	$5.02 - $6.59 $136,744 - $179,511	27,240 New	27,240 $154,000
Q2 2020 Aug 11, 2020	SELL	$3.32 - $5.34 $371,869 - $598,128	-112,009 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$2.12 - $6.8 $194,100 - $622,587	91,557 Added 447.67%	112,009 $382,000
Q4 2019 Feb 12, 2020	BUY	$2.25 - $5.8 $46,017 - $118,621	20,452 New	20,452 $104,000
Q1 2019 May 15, 2019	SELL	$2.41 - $5.91 $136,888 - $335,688	-56,800 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$3.94 - $9.7 $223,792 - $550,960	56,800 New	56,800 $273,000
Q3 2018 Nov 13, 2018	SELL	$8.6 - $11.26 $1 Million - $1.31 Million	-116,400 Closed	0 $0
Q2 2018 Aug 09, 2018	SELL	$9.52 - $12.15 $977,704 - $1.25 Million	-102,700 Reduced 46.87%	116,400 $1.13 Million
Q1 2018 May 11, 2018	SELL	$6.7 - $12.95 $343,937 - $664,775	-51,334 Reduced 18.98%	219,100 $2.31 Million
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $763,592 - $1.19 Million	150,610 Added 125.69%	270,434 $1.73 Million
Q3 2017 Nov 20, 2017	BUY	$5.4 - $8.47 $647,049 - $1.01 Million	119,824	119,824 $917,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account